Abstract
Receptor tyrosine kinases (RTKs) are transmembrane proteins that play a critical role in stimulating signal transduction cascades to influence cell proliferation, growth, and differentiation and they have also been shown to promote angiogenesis when they are up-regulated or mutated. For this reason, their dysfunction has been implicated in the development of human cancer. Over the past decade, much attention has been devoted to developing inhibitors and antibodies against several classes of RTKs, including vascular endothelial growth factor receptors (VEGFRs), epidermal growth factor receptors (EGFRs), and platelet-derived growth factor receptors (PDGFRs). More recently, interest in the fibroblast growth factor receptor (FGFR) class of RTKs as a drug target for the treatment of cancer has emerged. Signaling through FGFRs is critical for normal cellular function and their dysregulation has been linked to various malignancies such as breast and prostate cancer. This review will focus on the current state of both small molecules and antibodies as FGFR inhibitors to provide insight into their development and future potential as anti-cancer agents.
Keywords: Antibodies, ATP Binding Site, Cancer, Fibroblast Growth Factor Receptor, Indolinone, Pyrido[2, 3-d]pyrimidine, Small Molecules, Tyrosine Kinase Inhibitor.
Anti-Cancer Agents in Medicinal Chemistry
Title:Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer
Volume: 13 Issue: 5
Author(s): Steven M. Lemieux and M. Kyle Hadden
Affiliation:
Keywords: Antibodies, ATP Binding Site, Cancer, Fibroblast Growth Factor Receptor, Indolinone, Pyrido[2, 3-d]pyrimidine, Small Molecules, Tyrosine Kinase Inhibitor.
Abstract: Receptor tyrosine kinases (RTKs) are transmembrane proteins that play a critical role in stimulating signal transduction cascades to influence cell proliferation, growth, and differentiation and they have also been shown to promote angiogenesis when they are up-regulated or mutated. For this reason, their dysfunction has been implicated in the development of human cancer. Over the past decade, much attention has been devoted to developing inhibitors and antibodies against several classes of RTKs, including vascular endothelial growth factor receptors (VEGFRs), epidermal growth factor receptors (EGFRs), and platelet-derived growth factor receptors (PDGFRs). More recently, interest in the fibroblast growth factor receptor (FGFR) class of RTKs as a drug target for the treatment of cancer has emerged. Signaling through FGFRs is critical for normal cellular function and their dysregulation has been linked to various malignancies such as breast and prostate cancer. This review will focus on the current state of both small molecules and antibodies as FGFR inhibitors to provide insight into their development and future potential as anti-cancer agents.
Export Options
About this article
Cite this article as:
Lemieux M. Steven and Hadden Kyle M., Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/18715206113139990080
DOI https://dx.doi.org/10.2174/18715206113139990080 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Functions of Mammalian Germinal Center Kinases
Current Chemical Biology Editorial [Hot Topic: Transription Factors and their Modulated Genes as Targets for Chemoprevention (Guest Editor: Chuanshu Huang)]
Current Cancer Drug Targets Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry The Modification and Design of Antimicrobial Peptide
Current Pharmaceutical Design Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery The Anti-Inflammatory Role of Annexin-1 in Arthritis
Current Rheumatology Reviews Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Cytotoxic Effects of the Monomer and Dimer of 3, 4-seco-ent-kaurene from Croton Micans and their Interaction with Antitumoral Drugs on Cellular Line of Human Prostate Cancer
Letters in Drug Design & Discovery Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Recent Patents Review in Three Dimensional Ultrasound Imaging
Recent Patents on Biomedical Engineering (Discontinued) Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Current Topics in Medicinal Chemistry Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science